RNA Methylation is a common post-transcriptional modification in eukaryotes and prokaryotes. Methylation involves a methyl group transfer from an active methyl compound to another compound. RNA methylation can occur in both mRNA and ncRNA. RNA methylation includes m6A, m5C, m7G, and 2-O-methylation modifications. These modifications can affect the stability, splicing, and immunogenicity of RNA.
RNA methylation is involved in many physiological and pathological processes, especially for tumor immunity, where RNA methylation can affect the maturation and response function of immune cells. These modifications act to regulate the innate immunity of the body, through the influence of RNA immunogenicity and innate immune components. Recent research has suggested that RNA methylation has a role in the regulation of tumor immunity, which may represent a new avenue for tumor immunotherapy.
The most common nucleotide modification in most types of RNAs is N6-methylation of adenosine (m6A), which functions to regulate the expression of oncogenes or tumor suppressor genes. Recent studies explore a new role of m6A modification in tumor-associated immune cell activation and infiltration in the tumor microenvironment (TME). It also can affect the efficacy of classical immunotherapy, making m6A a potential target for immunotherapy. Although m6A modification may play contrasting roles in different tumor types, targeting m6A regulators has been shown to have wide implications in many cancers.
In this Research Topic, we aim to provide an update on the roles of RNA methylation in tumor immunity. We are also interested in the development of novel tumor immunotherapies targeting RNA methylation or its regulators. We welcome the submission of Original Research, Review, Mini Review, Clinical Trial, Opinion, and Perspective articles focusing on the roles and clinical implications of RNA methylation on tumor immunity. We welcome submissions covering, but not limited to, the following sub-topics:
• Reviews of our current understanding of the role of various RNA methylation modifications on tumor immunity
• Novel mechanistic studies into the role of RNA methylation in tumor immunity
• The control of RNA methylation by regulators and effect on tumor immunity
• Development of novel tumor immunotherapies targeting RNA methylation or its regulators
• Novel technologies to study the role of RNA methylation on tumor immunity and the development of tumor immunotherapies
*NOTE: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation are considered out of the scope of this Research Topic.
RNA Methylation is a common post-transcriptional modification in eukaryotes and prokaryotes. Methylation involves a methyl group transfer from an active methyl compound to another compound. RNA methylation can occur in both mRNA and ncRNA. RNA methylation includes m6A, m5C, m7G, and 2-O-methylation modifications. These modifications can affect the stability, splicing, and immunogenicity of RNA.
RNA methylation is involved in many physiological and pathological processes, especially for tumor immunity, where RNA methylation can affect the maturation and response function of immune cells. These modifications act to regulate the innate immunity of the body, through the influence of RNA immunogenicity and innate immune components. Recent research has suggested that RNA methylation has a role in the regulation of tumor immunity, which may represent a new avenue for tumor immunotherapy.
The most common nucleotide modification in most types of RNAs is N6-methylation of adenosine (m6A), which functions to regulate the expression of oncogenes or tumor suppressor genes. Recent studies explore a new role of m6A modification in tumor-associated immune cell activation and infiltration in the tumor microenvironment (TME). It also can affect the efficacy of classical immunotherapy, making m6A a potential target for immunotherapy. Although m6A modification may play contrasting roles in different tumor types, targeting m6A regulators has been shown to have wide implications in many cancers.
In this Research Topic, we aim to provide an update on the roles of RNA methylation in tumor immunity. We are also interested in the development of novel tumor immunotherapies targeting RNA methylation or its regulators. We welcome the submission of Original Research, Review, Mini Review, Clinical Trial, Opinion, and Perspective articles focusing on the roles and clinical implications of RNA methylation on tumor immunity. We welcome submissions covering, but not limited to, the following sub-topics:
• Reviews of our current understanding of the role of various RNA methylation modifications on tumor immunity
• Novel mechanistic studies into the role of RNA methylation in tumor immunity
• The control of RNA methylation by regulators and effect on tumor immunity
• Development of novel tumor immunotherapies targeting RNA methylation or its regulators
• Novel technologies to study the role of RNA methylation on tumor immunity and the development of tumor immunotherapies
*NOTE: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation are considered out of the scope of this Research Topic.